Author pages are created from data sourced from our academic publisher partnerships and public sources.
MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data
Single-cell transcriptomics reveals gene expression heterogeneity but suffers from stochastic dropout and characteristic bimodal expression distributions in which expression is either strongly… Expand
Immune-correlates analysis of an HIV-1 vaccine efficacy trial.
BACKGROUND In the RV144 trial, the estimated efficacy of a vaccine regimen against human immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case-control analysis to identify antibody and… Expand
The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation
Getting HIV Under Control Approximately 1 in 300 people infected with HIV are HIV “controllers” who are able to maintain long-term control of the virus without medication and who do not progress to… Expand
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis
- M. McElrath, S. Rosa, Z. Moodie, S. Dubey, the Step Study Protocol Team
- The Lancet
- 29 November 2008
BACKGROUND In the Step Study, the MRKAd5 HIV-1 gag/pol/nef vaccine did not reduce plasma viraemia after infection, and HIV-1 incidence was higher in vaccine-treated than in placebo-treated men with… Expand
Initial Events in Establishing Vaginal Entry and Infection by Human Immunodeficiency Virus Type-1
Summary Understanding the initial events in the establishment of vaginal human immunodeficiency virus type-1 (HIV-1) entry and infection has been hampered by the lack of appropriate experimental… Expand
HIV-1 Integration Landscape during Latent and Active Infection
The barrier to curing HIV-1 is thought to reside primarily in CD4(+) T cells containing silent proviruses. To characterize these latently infected cells, we studied the integration profile of HIV-1… Expand
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.
- S. Hammer, M. Sobieszczyk, +27 authors P. Gilbert
- The New England journal of medicine
- 27 November 2013
BACKGROUND A safe and effective vaccine for the prevention of human immunodeficiency virus type 1 (HIV-1) infection is a global priority. We tested the efficacy of a DNA prime-recombinant adenovirus… Expand
Setting the stage: host invasion by HIV
For more than two decades, HIV has infected millions of people worldwide each year through mucosal transmission. Our knowledge of how HIV secures a foothold at both the molecular and cellular levels… Expand
Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2.
BACKGROUND Most persons who are infected with human immunodeficiency virus type 1 (HIV-1) are also infected with herpes simplex virus type 2 (HSV-2), which is frequently reactivated and is associated… Expand
A Blueprint for HIV Vaccine Discovery.
Despite numerous attempts over many years to develop an HIV vaccine based on classical strategies, none has convincingly succeeded to date. A number of approaches are being pursued in the field,… Expand